Navigation Links
IU chemist develops new synthesis of most useful, yet expensive, antimalarial drug
Date:9/13/2012

BLOOMINGTON, Ind. -- In 2010 malaria caused an estimated 665,000 deaths, mostly among African children. Now, chemists at Indiana University have developed a new synthesis for the world's most useful antimalarial drug, artemisinin, giving hope that fully synthetic artemisinin might help reduce the cost of the live-saving drug in the future.

Effective deployment of ACT, or artemisinin-based combination therapy, has been slow due to high production costs of artemisinin. The World Health Organization has set a target "per gram" cost for artemisinin of 25 cents or less, but the current cost is about $2.40 per gram, and production of low-cost semi-synthetic artemisinin has yet to materialize.

"In 2005, the WHO claimed that the structure of artemisinin was too complex for cost-effective synthesis," said IU Bloomington College of Arts and Sciences chemistry professor Silas Cook. "We saw this as a natural challenge to the creativity and tenacity of organic chemists."

Published recently in the Journal of the American Chemical Society as "A Concise Synthesis of Artemisinin," Cook and postdoctoral co-author Chunyin Zhu report a succinct five-part process beginning with inexpensive cyclohexenone, an ideal feedstock available on metric-ton scale. Subsequent chemistry highlights several new reactions developed in the Cook group to enable this short, low-cost synthesis.

The result was the production of fully synthetic artemisinin on gram scale, greater than all previous total syntheses combined.

"The key to the ultimate success of synthetic artemisinin will be the large-scale production of the drug," Cook said. "As such, we had to completely rethink what qualified as suitable starting materials for this synthesis and invent new chemistry." The result was the use of readily available commodity chemicals in a process that was shorter than any other artemisinin total synthesis ever conducted.

The
'/>"/>

Contact: Steve Chaplin
stjchap@iu.edu
812-856-1896
Indiana University
Source:Eurekalert  

Page: 1 2

Related biology news :

1. LAMIS -- a green chemistry alternative for laser spectroscopy
2. UCLAs Yi Tang receives Presidential Green Chemistry Challenge Award from EPA
3. UC Berkeley chemists installing first carbon dioxide sensor network in Oakland
4. UMass Amherst biochemists developing tools to stop plague and other bacterial threats
5. Pulverized rocks, coral reefs, seawater chemistry, and continental collisions
6. Scientists connect seawater chemistry with climate change and evolution
7. Chemistry on Mars video with Curiosity Rover from the American Chemical Society
8. Chemists advance clear conductive thin films
9. Changes in water chemistry leave lake critters defenseless
10. Diabetes Research Institute develops oxygen-generating biomaterial
11. Genetic research develops tools for studying diseases, improving regenerative treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
IU chemist develops new synthesis of most useful, yet expensive, antimalarial drug
(Date:4/8/2015)... 8, 2015  Infinisource, a leading provider of SaaS-based ... Morpho, a leading supplier of biometric identification and ... market,s most advanced biometrically-enabled time clock, the companies ... clock is setting a bold, new standard for ... the small and mid-size employer. When connected to ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... make poisons similar to those found in rattlesnake venom ... (Monday 8 September 2008) at the Society for General ... College, Dublin. The toxins are manufactured by communities ... are up to a thousand times more resistant to ...
... new method to fabricate borosilicate glass nanoparticles. ... are more stable when subjected to temperature ... used nanoparticles made of polymers or silica ... of potential nanoparticle applications in biomedical, optical ...
... Science Foundation has awarded Iowa State University and ... to establish the NSF Engineering Research Center for ... award is part of the National Science Foundation,s ... third-generation Engineering Research Centers are designed to create ...
Cached Biology News:Rattlesnake-type poisons used by superbug bacteria to beat our defenses 2Rattlesnake-type poisons used by superbug bacteria to beat our defenses 3Iowa State wins $18.5M grant to create NSF Center for Biorenewable Chemicals 2Iowa State wins $18.5M grant to create NSF Center for Biorenewable Chemicals 3Iowa State wins $18.5M grant to create NSF Center for Biorenewable Chemicals 4
(Date:4/17/2015)... , April 17, 2015  Guggenheim Securities, the investment ... announced the hiring of William Tanner as ... Mr. Tanner will start work at Guggenheim in ... office. "Bill brings a wealth ... to our experienced and highly acclaimed healthcare team," said ...
(Date:4/17/2015)... MIAMI (PRWEB) April 17, 2015 ... attend the GTCbio Stem Cell Summit 2015 April 27 ... present the latest developments in all areas of stem ... business of stem cells and regenerative medicine. , ... clinical trials, as well as translational research in stem ...
(Date:4/17/2015)... 17, 2015 BellBrook Labs announced ... support for the powerful Orthogonal Pooled Screening (OPS) ... Center at the Lankenau Institute for Medical Research ... to measurably improve successful drug discovery outcomes using ... rare, drug-like libraries available nowhere else, coupled to ...
(Date:4/16/2015)... and OSAKA, Japan , April ... Application (CiRA) of Kyoto University and Takeda Pharmaceutical ... work together to develop clinical applications of induced ... failure, diabetes mellitus, neurological disorders and cancer immunotherapy. ... (T-CiRA) is designed to expedite multiple research projects ...
Breaking Biology Technology:Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3
... MYL ),today announced that Mylan Pharmaceuticals Inc. has ... (FDA) for its Abbreviated New,Drug Application (ANDA) for Ropinirole ... (base), 2 mg (base), 3 mg (base), 4 mg ... the generic version of,GlaxoSmithKline,s Requip(R) Tablets, which had total ...
... to Acquire Commercialized Thrombolytic and Related Assets for $17 ... ... Therapeutics, Inc.,(Nasdaq: IMRX ) today announced that it has signed a ... from ImaRx for $17 million in cash. Urokinase is an FDA-approved,thrombolytic, or ...
... ER May Impact Employment Status, WASHINGTON, ... (paliperidone ER) spent significantly,fewer days in the ... office visits, and fewer psychotherapy sessions,compared with ... a new,analysis of data presented at the ...
Cached Biology Technology:ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase 2ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase 3ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase 4Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources 2Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources 3Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources 4Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources 5Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources 6